Metformin Vitabalans (Metformin Hydrochloride)

Metformin Vitabalans belongs to the biguanide class and is employed in the management of disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels and helps achieve target HbA1c values.

• Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). This leads to decreased glucose production in the liver and enhanced glucose uptake in muscle and adipose tissue, improving overall glycemic control without stimulating insulin secretion.

Metformin Vitabalans may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, often early in therapy.
• Abdominal discomfort: cramping or pain.
• Metallic taste: transient alteration of taste perception.
• Weight loss: modest reduction in body weight.
• Vitamin B12 deficiency: reduced absorption over long‑term use.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic disturbance.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatotoxicity: abnormal liver function tests.
• Hypoglycemia: uncommon when used alone.
• Anemia: due to B12 deficiency.
• Acute pancreatitis: very rare occurrence.

Metformin Vitabalans requires careful consideration of patient‑specific factors before initiation.

• Renal function: avoid or adjust dose in patients with impaired creatinine clearance.
• Hepatic impairment: use with caution in liver disease.
• Contrast imaging: discontinue before iodinated contrast procedures.
• Alcohol consumption: limit intake to reduce lactic acidosis risk.
• Elderly patients: monitor for renal function and dehydration.
• Pregnancy category: safety not established; assess risk‑benefit.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin Vitabalans can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: increase risk of lactic acidosis.
• Cimetidine: may raise metformin plasma concentrations.
• Alcohol: potentiates lactic acidosis.
• Diuretics (loop or thiazide): may impair renal clearance.
• Antiretrovirals (e.g., didanosine): heightened toxicity risk.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor renal function and potassium.
• Beta‑blockers: may mask hypoglycemia symptoms.
• Other antidiabetic agents: adjust dose to avoid hypoglycemia.
• Thyroid hormones: may affect glucose metabolism.
• Digoxin: monitor for altered renal clearance.